Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab.
<p>BACKGROUND: The ability to image vascular endothelial growth factor (VEGF) could enable prospective, non-invasive monitoring of patients receiving anti-angiogenic therapy. This study investigates the specificity and pharmacokinetics of (111)In-bevacizumab binding to VEGF and its use for ass...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2017
|